LISATA THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $170,000 | $1.0M | $0 | $0 | — |
| Selling, general & administrative | — | — | $13.0M | $14.1M | $11.5M |
| Research and development | $7.9M | $11.3M | $12.7M | $13.1M | $17.7M |
| Operating expenses | $18.4M | $23.4M | $25.7M | $57.6M | $29.1M |
| Operating income | -$18.2M | -$22.4M | -$25.7M | -$57.6M | -$29.1M |
| Pretax income | -$17.5M | -$20.8M | -$23.2M | -$56.7M | -$29.0M |
| Income tax expense | -$962,000 | -$798,000 | -$2.3M | -$2.5M | -$1.5M |
| Net income | -$16.6M | -$20.0M | -$20.8M | -$54.2M | -$27.5M |
| Balance Sheet | |||||
| Cash and equivalents | $16.0M | $16.2M | $22.6M | $32.2M | $24.6M |
| Current assets | $17.7M | $34.6M | $53.9M | $71.9M | $96.2M |
| Total assets | $17.7M | $35.0M | $54.7M | $73.0M | $97.0M |
| Current liabilities | $3.1M | $5.6M | $6.6M | $6.4M | $4.5M |
| Total liabilities | $3.1M | $5.7M | $6.8M | $6.7M | $5.0M |
| Stockholders' equity | $14.9M | $29.6M | $48.1M | $66.6M | $92.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$15.9M | -$19.4M | -$20.0M | -$21.2M | -$22.2M |
| Depreciation and amortization | $100,000 | $100,000 | $189,000 | $69,000 | $55,000 |
| Stock-based compensation | $1.2M | $1.7M | $2.0M | $2.6M | $2.0M |
| Capital expenditure | $28,000 | $0 | $0 | $285,000 | $60,000 |
| Free cash flow | -$16.0M | -$19.4M | -$20.0M | -$21.5M | -$22.3M |
Shares outstanding 9.1M · Free float 66.1%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.